ASH Annual Meeting and Exposition | Conference

Nivolumab-Brentuximab Vedotin Combo Active and Safe in Relapsed Hodgkin Lymphoma

December 8th 2016

Early data from a phase I/II study suggest that the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) may be an active and well-tolerated outpatient regimen in patients with relapsed/refractory classical Hodgkin lymphoma after failure of standard frontline chemotherapy.

High Response Rate With Venetoclax in Relapsed/Refractory CLL

December 8th 2016

Two thirds of patients with chronic lymphocytic leukemia (CLL) that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax, results of a small open-label trial showed.

Dr. Jackson on Lenalidomide as a Highly-Effective Maintenance Therapy in Myeloma

December 7th 2016

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

KTE-C19 Leads to High Response Rates in Refractory NHL

December 7th 2016

Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.

Ibrutinib Shows Promise in Treating GVHD After Stem Cell Transplant

December 7th 2016

An FDA-approved blood cancer drug has demonstrated encouraging findings, including an overall response rate of 67%, in treatment of patients with chronic graft-versus-host-disease that was not resolved by corticosteroids.

Dr. Woyach on a Study Combining MOR208 With Lenalidomide for the Treatment of CLL

December 7th 2016

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.

Subcutaneous Daratumumab Safe, Effective in Myeloma

December 6th 2016

Subcutaneous delivery of daratumumab was well tolerated with comparable efficacy to the FDA-approved intravenous dose in patients with relapsed/refractory multiple myeloma.

Venetoclax Highly Effective With Bortezomib/Dexamethasone for Multiple Myeloma

December 6th 2016

Adding venetoclax to bortezomib and dexamethasone showed very promising efficacy and acceptable safety for patients with relapsed/refractory multiple myeloma.

Selinexor Active in Heavily Pretreated Myeloma

December 6th 2016

Selinexor, in combination with dexamethasone, induced a response rate of 20.5% (n = 16) among 78 heavily pretreated patients with relapsed/refractory multiple myeloma, according to results from the phase IIb STORM trial presented at the 2016 ASH Annual Meeting.

Dr. Gisslinger on a Study Comparing Ropeginterferon Alfa-2b to Hydroxyurea in PV

December 6th 2016

Heinz Gisslinger, MD, Medical University of Vienna, discusses the phase III PROUD-PV study, which evaluated ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera (PV) during the American Society of Hematology (ASH) Annual Meeting.

KTE-C19 Response Rates Spark FDA Submission for Aggressive Lymphomas

December 6th 2016

Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma.

Early Study Signals Promising Role for Venetoclax in Treatment of Relapsed CLL

December 6th 2016

Adding the oral BCL-2 inhibitor venetoclax (Venclexta) to obinutuzumab (Gazyva) and ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia is safe and is demonstrating encouraging signs of efficacy.

Ibrutinib Regimen Induces 100% Induction Response in CLL

December 6th 2016

An induction regimen of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia.

BGB-3111 Response Rate Nears 100% in CLL/SLL

December 6th 2016

Treatment with the BTK inhibitor BGB-3111 had an objective response rate of 96% for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

Acalabrutinib Safe, Effective in Ibrutinib-Intolerant CLL/SLL

December 6th 2016

The investigational Bruton tyrosine kinase inhibitor acalabrutinib was shown to be well-tolerated in patients with chronic lymphocytic leukemia and small lymphocytic leukemia who display intolerance to ibrutinib (Imbruvica).

TGR-1202/Ibrutinib Combo Feasible, Highly Active for CLL/MCL

December 5th 2016

The combination of the PI3 kinase inhibitor TGR-1202 and ibrutinib demonstrated a high response rate without dose-limiting toxicities for patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Burke on a Study Investigating Obinutuzumab in Large B-Cell Lymphoma

December 5th 2016

John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.

Frontline Obinutuzumab Significantly Improves PFS in Follicular Lymphoma

December 5th 2016

Combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.

Pembrolizumab Combo Highly Effective for Heavily Pretreated Myeloma

December 5th 2016

Treatment with the combination of pembrolizumab, pomalidomide, and dexamethasone demonstrated promising durable efficacy and a tolerable safety profile for patients with relapsed/refractory multiple myeloma.

Dr. Thompson on Exciting Advancements in the Field of Multiple Myeloma

December 5th 2016

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the recent exciting advancements in the field of multiple myeloma during the American Society of Hematology (ASH) Annual Meeting.